速递｜来凯医药LAE102：四周增肌减脂显著，开创增肌减脂新纪元

Core Insights - The article highlights the significant breakthrough of LAE102, a drug developed by the company, in the competitive global metabolism and weight loss market, showcasing its potential to attract attention from both capital markets and clinical fields [4] Group 1: Drug Performance - LAE102 demonstrated remarkable results in a Phase I single-dose escalation study in the U.S., showing significant muscle gain and fat loss effects in healthy postmenopausal women after 4 weeks of treatment, with a 5.06% increase in lean body mass and a 0.12% decrease in fat mass compared to a placebo group [4] - Compared to competitors, LAE102 outperformed Bimagrumab in muscle gain within 4-5 weeks, while also showing strong fat loss effects, indicating its superior efficacy in the "muscle gain and fat loss" arena [5] Group 2: Safety and Development - The safety profile of LAE102 is impressive, with no serious adverse events reported, aligning closely with previous Phase I trial results in China, which enhances its potential as a leading drug in the muscle gain and fat loss sector [5] - The company is accelerating the development of LAE102 and actively engaging with potential partners to expedite global commercialization, positioning it as a highly sought-after project among major pharmaceutical companies in the future [6]